Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene

BMJ Open Diabetes Research and Care

Volumn 8, Issue 1, 2020, Pages

  Yang, Jeff Yufeng ^a   Wang, Tiansheng ^a   Pate, Virginia ^a   Buse, John B ^b   Stürmer, Til ^a  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

analytic methods; claims database analysis; epidemiology; sodium glucose cotransporter

Indexed keywords

ANTIBIOTIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; BIOLOGICAL MARKER;

ADMINISTRATIVE CLAIMS (HEALTH CARE); ADULT; ANTIDIABETIC ACTIVITY; ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; FEMALE; FOLLOW UP; FOURNIER GANGRENE; HOSPITALIZATION; HUMAN; ICD-10; ICD-9; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROPENSITY SCORE; RISK; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; ADVERSE EVENT; INCIDENCE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

BIOMARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; FOURNIER GANGRENE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; UNITED STATES;

EID: 85078326476     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2019-000985     Document Type: Article

References (30)

1. FDA. Fda warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes, 2018. Available: https://www. fda. gov/ Drugs/ DrugSafety/ ucm617360. htm
2. Sorensen MD, Krieger JN. Fournier's gangrene: epidemiology and outcomes in the general US population. Urol Int 2016;97:249-59.
3. Kranz J, Schlager D, Anheuser P, et al. Desperate need for better management of Fournier's Gangrene. Cent Eur J Urol 2018;71:360-5.
4. Sorensen MD, Krieger JN, Rivara FP, et al. Fournier's gangrene: management and mortality predictors in a population based study. J Urol 2009;182:2742-7.
5. Sorensen MD, Krieger JN, Rivara FP, et al. Fournier's gangrene: population based epidemiology and outcomes. Journal of Urology 2009;181:2120-6.
6. Singh A, Ahmed K, Aydin A, et al. Fournier's gangrene. A clinical review. Arch Ital Urol Androl 2016;88:157-64.
7. Lee BY. How one class of diabetes medications may lead to flesh-eating genital infections, 2018. Available: https://www. forbes. com/ sites/ brucelee/ 2018/ 09/ 01/ how-one-class-of-diabetes-medicationsmay-lead-to-flesh-eating-genital-infections/# 75c509976193
8. Chi WC, Lim-Tio S. Fournier's syndrome: A life threatening complication of SGLT2 inhibition in poorly controlled diabetesmellitus (Poster #265). Available: http:// ads-adea-2016. m. Asnevents. com. Au/ schedule/ session/ 9239/ abstract/ 36604
9. Kumar S, Costello AJ, Colman PG. Fournier's gangrene in a man on empagliflozin for treatment of Type 2 diabetes. Diabet. Med. 2017;34:1646-8.
10. Onder CE, Gursoy K, Kuskonmaz SM, et al. Fournier's gangrene in a patient on dapagliflozin treatment for type 2 diabetes. J Diabetes 2019;11:348-50.
11. Bersoff-Matcha SJ, Chamberlain C, Cao C, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases. Ann Intern Med 2019;170:764-9.
12. Bloomgarden Z, Einhorn D, Grunberger G, Handelsman Y, et al. Fournier's gangrene and sodium-glucose cotransporter 2 inhibitors: is there a causal association J Diabetes 2019;11:340-1.
13. Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep 2015;2:221-8.
14. Mosley JF, Smith L, Everton E, et al. Sodium-Glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: A drug class overview. Pharm Ther 2015;40:451-62.
15. Agarwal S, Pitcavage JM, Sud K, et al. Burden of readmissions among patients with critical limb ischemia. J Am Coll Cardiol 2017;69:1897-908.
16. Brennan MB, Allen GO, Ferguson PD, et al. The association between geographic density of infectious disease physicians and limb preservation in patients with diabetic foot ulcers. Open Forum Infect Dis 2017;4:1-8.
17. Turley RS, Mi X, Qualls LG, et al. The Effect of Clinical Care Location on Clinical Outcomes After Peripheral Vascular Intervention in Medicare Beneficiaries. JACC: Cardiovascular Interventions 2017;10:1161-71.
18. Eggers PW, Gohdes D, Pugh J. Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int 1999;56:1524-33.
19. Goldberg JB, Goodney PP, Cronenwett JL, et al. The effect of risk and race on lower extremity amputations among Medicare diabetic patients. J Vasc Surg 2012;56:1663-8.
20. Martinson M, Martinson N. A comparative analysis of skin substitutes used in the management of diabetic foot ulcers. J Wound Care 2016;25:S8-17.
21. McEwen LN, Ylitalo KR, Munson M, et al. Foot complications and mortality: results from translating research into action for diabetes (triad). J Am Podiatr Med Assoc 2016;106:7-14.
22. Medhekar AN, Mix DS, Aquina CT, et al. Outcomes for critical limb ischemia are driven by lower extremity revascularization volume, not distance to hospital. J Vasc Surg 2017;66:476-87.
23. Newhall K, Spangler E, Dzebisashvili N, et al. Amputation rates for patients with diabetes and peripheral arterial disease: The effects of race and region. Ann Vasc Surg 2016;30:292-8.
24. Newhall K, Stone D, Svoboda R, et al. Possible consequences of regionally based bundled payments for diabetic amputations for safety net hospitals in Texas. J Vasc Surg 2016;64:1756-62.
25. Sargen MR, Hoffstad O, Margolis DJ. Geographic variation in Medicare spending and mortality for diabetic patients with foot ulcers and amputations. J Diabetes Complications 2013;27:128-33.
26. CMS. 2018 ICD-10 CM and GEMs. Available: https://www. cms. gov/ Medicare/ Coding/ ICD10/ 2018-ICD-10-CM-and-GEMs. html [Accessed 5 May 2019].
27. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J 2009;51:171-84.
28. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology 2003;14:680-6.
29. Montvida O, Shaw J, Atherton JJ, et al. Long-term trends in antidiabetes drug usage in the U. S. : real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care 2018;41:69-78.
30. Silverii GA, Dicembrini I, Monami M, et al. Fournier's gangrene and sodium-glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 2019. doi:10. 1111/dom. 13900. [Epub ahead of print: 21 Oct 2019].